# Implementation of Biomarkers

**Funder:** KWF
**Budget:** €1M–€4M
**Deadline:** 20 October 2026 (Pre-proposal deadline 12:00 noon; full proposal deadline 23 February 2027 (12:00 noon))
**Duration:** 3-5 years
**Consortium:** Required — minimum 4 participating parties (may include private partners)
**Application:** 2-stage: pre-proposal (opens 25 Aug 2026, closes 20 Oct 2026) → full proposal (opens 15 Dec 2026, closes 23 Feb 2027) → interviews May 2027 → funding decision June 2027
**TRL:** 7-9
**Frequency:** Annual
**Eligible countries:** NL
**Official call:** https://www.kwf.nl/en/forresearchers/funding/implementation-of-biomarkers-2027
**Last verified:** 5 July 2026

## Eligibility & scope

Open to multidisciplinary consortia (min. 4 parties) aiming to implement a clinically validated biomarker (TRL 7–9) into nationwide routine oncology care in the Netherlands. Mandatory components include an HTA specialist in the team, a KWF-approved steering committee, and a patient perspective embedded throughout. Public-private collaborations encouraged with co-funding. PhD candidates strongly discouraged. Proposals must be submitted via KWF GMS.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/kwf-implementation-of-biomarkers-2026-10) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.